DFDA

Surgical Resection

Treatment for Liver Cancer Due To Hepatitis C

Effectiveness
85%
Safety Score
50%
Clinical Trials
500
Participants
100K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate (tumor removal), long-term survival benefit
Treatment Duration
One-time surgery, followed by surveillance
Evidence Quality
HIGH
Number Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$3,500
Side Effect Mgmt:$2,000
Total Annual:$5,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$100,000/QALY
QALYs Gained
5
Surgical Resection Outcomes

for Liver Cancer Due To Hepatitis C

Efficacy Outcomes
Overall Effectiveness
+85%
Remission Rate
+60%
Common Side Effects
Postoperative liver failure
+7%
Bleeding
+15%
Infection
+10%
Recurrence
+50%

Sources:

ctfassets.net
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov